Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, and Phil Scalfani, PwC’s Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration’s executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead.

Discussion Highlights:

The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countries
Pharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroad
A proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)
Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developments

Speakers:

Glenn Hunzinger, Health Industries Leader, PwC
Philip Sclafani, Partner, Pharma & Life Sciences, PwC

Linked materials:

Most Favored Nation prescription drug pricing Executive Order

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Taking a closer look at the Most Favored Nation Pricing Executive Order